Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1159/000218081. Epub 2009 May 12.
Affiliations
- PMID: 19439966
- DOI: 10.1159/000218081
Randomized Controlled Trial
Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study
Yvonne Freund-Levi et al. Dement Geriatr Cogn Disord. 2009.
Abstract
Background: omega-3 fatty acids (omega-3 FAs) found in dietary fish or fish oils are anti-inflammatory agents that may influence Alzheimer's disease (AD).
Objective: To study the effects of dietary omega-3 FA supplementation on inflammatory markers in cerebrospinal fluid (CSF) and plasma from patients with mild to moderate AD.
Methods: Thirty-five patients (70.3 +/- 8.2 years) were randomized to a daily intake of 2.3 g omega-3 FAs or placebo for 6 months. The inflammatory markers interleukin (IL)-6, tumour necrosis factor-alpha and soluble interleukin-1 receptor type II (sIL-1RII) were analysed in CSF and plasma at baseline and at 6 months. The AD markers tau-protein, hyperphosphorylated tau-protein and beta-amyloid (Abeta(1-42)) were assessed in CSF. High-sensitivity C-reactive protein was assessed in plasma. A possible relation to the APOE genotype was investigated.
Results: There was no significant treatment effect of omega-3 FAs on inflammatory and AD biomarkers in CSF or on inflammatory markers in plasma, nor was there any relation with APOE. A significant correlation was observed at baseline between sIL-1RII and Abeta(1-42) levels in CSF.
Conclusions: Treatment of AD patients with omega-3 FAs for 6 months did not influence inflammatory or biomarkers in CSF or plasma. The correlation between sIL-1RII and Abeta(1-42) may reflect the reciprocal interactions between IL-1 and Abeta peptides.
Similar articles
- Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study.
Freund Levi Y, Vedin I, Cederholm T, Basun H, Faxén Irving G, Eriksdotter M, Hjorth E, Schultzberg M, Vessby B, Wahlund LO, Salem N Jr, Palmblad J. Freund Levi Y, et al. J Intern Med. 2014 Apr;275(4):428-36. doi: 10.1111/joim.12166. Epub 2014 Jan 11. J Intern Med. 2014. PMID: 24410954 Clinical Trial. - Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study.
Irving GF, Freund-Levi Y, Eriksdotter-Jönhagen M, Basun H, Brismar K, Hjorth E, Palmblad J, Vessby B, Vedin I, Wahlund LO, Cederholm T. Irving GF, et al. J Am Geriatr Soc. 2009 Jan;57(1):11-7. doi: 10.1111/j.1532-5415.2008.02055.x. Epub 2008 Nov 20. J Am Geriatr Soc. 2009. PMID: 19054188 Clinical Trial. - Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J. Freund-Levi Y, et al. Arch Neurol. 2006 Oct;63(10):1402-8. doi: 10.1001/archneur.63.10.1402. Arch Neurol. 2006. PMID: 17030655 Clinical Trial. - Plasma biomarkers of Alzheimer's disease.
Kawarabayashi T, Shoji M. Kawarabayashi T, et al. Curr Opin Psychiatry. 2008 May;21(3):260-7. doi: 10.1097/YCO.0b013e3282fc989f. Curr Opin Psychiatry. 2008. PMID: 18382225 Review. - Amyloid beta and APP as biomarkers for Alzheimer's disease.
Zetterberg H, Blennow K, Hanse E. Zetterberg H, et al. Exp Gerontol. 2010 Jan;45(1):23-9. doi: 10.1016/j.exger.2009.08.002. Epub 2009 Aug 19. Exp Gerontol. 2010. PMID: 19698775 Review.
Cited by
- The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial.
Burns DK, Chiang C, Welsh-Bohmer KA, Brannan SK, Culp M, O'Neil J, Runyan G, Harrigan P, Plassman BL, Lutz M, Lai E, Haneline S, Yarnall D, Yarbrough D, Metz C, Ponduru S, Sundseth S, Saunders AM. Burns DK, et al. Alzheimers Dement (N Y). 2019 Oct 28;5:661-670. doi: 10.1016/j.trci.2019.09.010. eCollection 2019. Alzheimers Dement (N Y). 2019. PMID: 31720367 Free PMC article. - Effect of marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6 and tumor necrosis factor α: a meta-analysis.
Li K, Huang T, Zheng J, Wu K, Li D. Li K, et al. PLoS One. 2014 Feb 5;9(2):e88103. doi: 10.1371/journal.pone.0088103. eCollection 2014. PLoS One. 2014. PMID: 24505395 Free PMC article. - Fatty Acid-Binding Protein 5 at the Blood-Brain Barrier Regulates Endogenous Brain Docosahexaenoic Acid Levels and Cognitive Function.
Pan Y, Short JL, Choy KH, Zeng AX, Marriott PJ, Owada Y, Scanlon MJ, Porter CJ, Nicolazzo JA. Pan Y, et al. J Neurosci. 2016 Nov 16;36(46):11755-11767. doi: 10.1523/JNEUROSCI.1583-16.2016. J Neurosci. 2016. PMID: 27852782 Free PMC article. - APP Function and Lipids: A Bidirectional Link.
Grimm MO, Mett J, Grimm HS, Hartmann T. Grimm MO, et al. Front Mol Neurosci. 2017 Mar 10;10:63. doi: 10.3389/fnmol.2017.00063. eCollection 2017. Front Mol Neurosci. 2017. PMID: 28344547 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous